Condition: Primary Biliary Cholangitis · PBC · Sponsor: Mirum Pharmaceuticals, Inc.
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Southern California Research Center | Coronado, California, United States | Terminated |
| Cedars Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| University of California Los Angeles | Los Angeles, California, United States | Recruiting |
| UC Davis | Sacramento, California, United States | Recruiting |
| University of Colorado | Aurora, Colorado, United States | Recruiting |
| Yale University Digestive Diseases | New Haven, Connecticut, United States | Recruiting |
| Covenant Metabolic Specialists | Fort Myers, Florida, United States | Terminated |
| UF Hepatology Research at CTRB | Gainesville, Florida, United States | Recruiting |
| UF Health Gastroenterology- Emerson | Jacksonville, Florida, United States | Terminated |
| IHS Health | Kissimmee, Florida, United States | Terminated |
| Schiff Center for Liver Diseases | Miami, Florida, United States | Terminated |
| Advanced Research Institute, Inc | New Port Richey, Florida, United States | Recruiting |
+ 118 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05050136